FDA Warning Letters

Seven Warning Letters Signal Increased FDA Scrutiny

The U.S. Food and Drug Administration (FDA) has launched a coordinated enforcement action against websites marketing unapproved ketamine-related drug products, issuing seven Warning Letters on July 7, 2026, to online sellers the agency says are illegally offering unapproved and misbranded drugs to U.S. consumers.

The letters, issued by FDA’s Center for Drug Evaluation and Research (CDER), target companies marketing ketamine and related products over the internet, including products intended to treat depression and other serious medical conditions without FDA approval.

The coordinated action suggests FDA is increasing its enforcement focus on online drug sales involving ketamine and other emerging therapies.

FDA raises patient safety concerns

Unlike many enforcement actions that begin by describing regulatory violations, FDA opens each Warning Letter by emphasizing the potential risks to patients.

According to the agency, consumers purchasing unapproved ketamine products online may face serious health risks, particularly when products are used without appropriate medical supervision.

FDA also warns that injectable drug products present additional concerns because they bypass many of the body’s natural defenses, potentially exposing patients to contaminated or counterfeit products capable of causing severe infections such as septicemia or sepsis.

The agency further notes that unapproved drugs may contain varying amounts of active ingredients, contain different ingredients than advertised, be contaminated or counterfeit, lack demonstrated safety and effectiveness, or be marketed without adequate prescribing information or physician oversight.

FDA concluded that the easy availability of these products through internet sales “puts U.S. consumers at risk for serious adverse events.”

Marketing unapproved drugs online

The Warning Letters allege that the companies introduced unapproved new drugs and misbranded prescription drugs into interstate commerce in violation of multiple provisions of the Federal Food, Drug, and Cosmetic Act.

Among the concerns identified by FDA were marketing ketamine products for treatment-resistant depression and other medical conditions without FDA approval, offering prescription drugs directly to consumers over the internet, marketing products that lack adequate directions for safe use, and selling products subject to additional regulatory controls, including Risk Evaluation and Mitigation Strategy (REMS) requirements.

FDA requested that each company immediately stop offering the identified products for sale to U.S. consumers.

A coordinated enforcement initiative

The Warning Letters were all issued on June 23, 2026, and publicly posted on July 7, 2026, indicating a coordinated enforcement effort rather than isolated regulatory actions.

The companies identified include LyfeUnit, All Ketamine HCL, Med Shop Inc., Ketamine Troche Store, Buy Keta Online, Ketamine Store, and Pure Arylcyclohexylamine Store.

Although each letter addresses a specific website, the allegations and regulatory concerns are substantially similar. The coordinated timing sends a broader message to companies marketing unapproved ketamine products directly to U.S. consumers.

Growing interest, growing oversight

FDA acknowledged the increasing public interest in ketamine therapies, particularly for conditions such as treatment-resistant depression.

At the same time, the agency emphasized that increased consumer demand does not eliminate the legal requirements governing the marketing of prescription drugs in the United States.

The Warning Letters reinforce FDA’s longstanding position that products intended to diagnose, treat, mitigate, cure, or prevent disease generally require FDA approval before being marketed to consumers.

MDP perspective

These Warning Letters represent more than routine enforcement actions against individual websites.

Collectively, they illustrate FDA’s continued focus on internet-based drug marketing and the agency’s willingness to pursue coordinated enforcement when it identifies broader patterns of potential public health risk.

The growing interest in innovative therapies such as ketamine presents important opportunities for medical advancement. However, FDA’s actions demonstrate that innovation and consumer demand do not replace the statutory requirements intended to ensure that prescription drugs are manufactured, labeled, distributed, and marketed in a manner that protects patient safety.

For companies operating in rapidly evolving therapeutic markets, regulatory compliance should be viewed not as an obstacle to innovation, but as an essential component of building trust with healthcare providers, patients, and regulators.